Omeprazole (A2845): Practical Research Guidance

Omeprazole (SKU A2845) is supplied as a research compound described as an H+,K+-ATPase inhibitor. The product dossier identifies it as 3-(quinolin-4-ylmethylamino)-N-[4-(trifluoromethoxy)phenyl]thiophene-2-carboxamide, with a molecular weight of 345.42 and formula C17H19N3O3S. Use the Omeprazole product information to confirm the current specification and handling details before beginning an experiment. This guide focuses on practical assay setup, vehicle handling, and interpretation boundaries when directly matched paper evidence is unavailable.

What This Product Solves

In gastric acid secretion research, a defined inhibitor can help test whether an experimental readout changes when H+,K+-ATPase activity is suppressed. Omeprazole is therefore relevant to studies of acid secretion, antiulcer activity, and selected peptic ulcer disease models. The dossier reports an IC50 of 5.8 μM for H+,K+-ATPase inhibition and an IC50 of 0.16 μM for inhibition of histamine-induced acid formation. These are product-reported reference values, not universal working concentrations: assay format, preparation, biological system, and endpoint can affect observed responses.

Use the compound to investigate a specified experimental question, rather than treating acid suppression as a substitute for measuring the mechanism or phenotype of interest. In a gastric acid-related disorders model, for example, distinguish a direct acid-secretion endpoint from downstream outcomes such as lesion-related readouts. Each requires its own controls and interpretation. For a related overview of experimental planning, see Omeprazole (A2845): Protocol Guidance for Gastric Acid Research; this article emphasizes practical preparation and QC considerations.

Protocol Parameters

• Assay: H+,K+-ATPase inhibition. Value: IC50 5.8 μM. Applicability: Product-reported reference for the stated enzyme-inhibition context. Rationale: Provides a starting benchmark for planning a concentration-response experiment, not a guaranteed potency in other assay formats. Basis: Product dossier.
• Assay: Histamine-induced acid formation. Value: IC50 0.16 μM. Applicability: Reference for the reported acid-formation endpoint; confirm compatibility with the selected model and readout. Rationale: This functional endpoint is distinct from the enzyme assay and should not be substituted for its value. Basis: Product dossier.
• Assay: Stock preparation and vehicle selection. Value: Solubility is reported as at least 17.27 mg/mL in DMSO; insoluble in water and ethanol. Applicability: Use the stated DMSO solubility as a preparation reference, not as a recommended final assay concentration. Rationale: A compatible solvent and matched vehicle control help separate compound effects from solvent effects. Basis: Product dossier; final vehicle conditions require assay-specific validation.
• Assay: Identity and incoming-material QC. Value: Molecular weight 345.42; purity approximately 98%. Applicability: Use the molecular weight for preparation calculations and purity as the stated product specification. Rationale: Recording these details supports traceability and accurate stock preparation. Basis: Product dossier.

Workflow Setup and QC Checklist

1. Define the endpoint first. Decide whether the primary measurement is enzyme inhibition, acid formation, or a downstream phenotype. Record the biological system, stimulation condition, readout, and analysis plan before selecting a working concentration. The dossier values can inform initial planning, but a local concentration-response experiment is needed to establish conditions for the specific assay.
2. Plan solvent controls alongside compound conditions. Because the compound is reported insoluble in water and ethanol but soluble in DMSO, prepare it using a compatible DMSO-based approach. Keep the final vehicle consistent across relevant wells or samples, and include a vehicle-only control. Avoid interpreting a response as compound-specific if the vehicle differs between treatment and control groups.
3. Prepare and track the material carefully. Calculate the required mass using the stated molecular weight, then document the actual mass, solvent, concentration, lot, preparation date, and operator. Inspect the preparation for visible material that has not dissolved. Do not assume that a nominal concentration represents a fully dissolved preparation.
4. Minimize solution-storage uncertainty. The dossier recommends storage as a solid at -20°C and does not recommend long-term storage in solution. Keep the solid under the stated storage condition and prepare solution for the planned work. If solution storage is unavoidable, establish and document stability under the laboratory’s own conditions rather than assuming it from the solid-storage specification.
5. Include assay-appropriate controls and QC. Use untreated or baseline controls where appropriate, a matched vehicle control, and a validated reference condition if the assay requires one. Confirm that the assay is functioning independently of the compound, and retain raw data and preparation records. For acid-formation assays, verify that the stimulation and detection steps produce a measurable response before attributing changes to inhibition.
6. Check receipt and handling records. The product dossier specifies blue-ice shipping for small molecules. On receipt, record package condition and product details, then store the solid according to the stated specification. Follow institutional chemical-handling procedures and consult the applicable safety documentation.

Common Failure Modes and Fixes

Precipitation or inconsistent dosing

A common source of variability is treating a calculated concentration as proof that the compound is dissolved. The stated aqueous insolubility makes direct addition of a concentrated preparation to an aqueous assay especially important to validate. Check for visible precipitation after dilution, keep mixing and addition procedures consistent, and assess whether the final vehicle level is compatible with the assay. If the preparation is not uniform, do not interpret nominal dose as delivered exposure.

Vehicle effects mistaken for inhibition

DMSO can affect biological readouts depending on the system. Keep the vehicle matched between compound and control conditions and verify that the selected vehicle level does not compromise assay performance. If the vehicle cannot be held constant across a concentration series, redesign the dilution scheme or interpret the affected comparisons cautiously.

Using a reported IC50 as a fixed dose

An IC50 is tied to its assay context and endpoint. The 5.8 μM enzyme value and 0.16 μM histamine-induced acid-formation value are not interchangeable, and neither establishes an effective concentration in a different cell, tissue, or organism model. Use a local titration and report the assay conditions with the result.

Loss of reproducibility between runs

Differences in stock preparation, time in solution, vehicle composition, or stimulation conditions can shift the response. Standardize these steps, retain preparation records, and compare runs using the same control structure. If the response changes, review compound handling and assay performance before assigning a biological explanation.

Scope and Limitations

This guidance is based on the product dossier and general workflow practice; it is not a substitute for directly matched published evidence or validation in a particular model. The reported potency values should be treated as context-specific product information, not as independently verified outcomes across assay types. The dossier also reports approximately 98% purity; researchers should set acceptance criteria appropriate to their study and verify that the received material and handling records meet their requirements.

Omeprazole A2845 is intended strictly for scientific research use and is not for diagnostic or medical purposes. The product information does not establish efficacy, safety, or dosing for clinical use. Conclusions from gastric acid secretion experiments should be limited to the measured endpoints and model conditions; a change in acid-related readouts alone does not establish broader antiulcer effects.

Conclusion

Omeprazole A2845 can support controlled experiments on H+,K+-ATPase inhibition and gastric acid secretion when solubility, vehicle effects, endpoint selection, and storage are managed explicitly. Use dossier-reported values as planning references, establish working conditions in the selected assay, and maintain a matched control and traceable preparation record. These practices make findings easier to interpret without extending conclusions beyond the evidence generated in the model.